Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs. More Details
Excellent balance sheet with weak fundamentals.
Share Price & News
How has Gongwin Biopharm Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 6617 is more volatile than 75% of TW stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: 6617's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of TW stocks.
7 Day Return
1 Year Return
Return vs Industry: 6617 exceeded the TW Biotechs industry which returned 21.9% over the past year.
Return vs Market: 6617 exceeded the TW Market which returned 31.3% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Gongwin Biopharm Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
8 months ago | Simply Wall StWe Think Gongwin Biopharm Holdings (GTSM:6617) Can Easily Afford To Drive Business Growth
10 months ago | Simply Wall StImagine Owning Gongwin Biopharm Holdings (GTSM:6617) And Wondering If The 15% Share Price Slide Is Justified
1 year ago | Simply Wall StHealth Check: How Prudently Does Gongwin Biopharm Holdings (GTSM:6617) Use Debt?
Is Gongwin Biopharm Holdings undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 6617's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 6617's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 6617 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.
PE vs Market: 6617 is unprofitable, so we can't compare its PE Ratio to the TW market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 6617's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 6617 is overvalued based on its PB Ratio (38.3x) compared to the TW Biotechs industry average (4.8x).
How is Gongwin Biopharm Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Gongwin Biopharm Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Gongwin Biopharm Holdings's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Gongwin Biopharm Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6617 is currently unprofitable.
Growing Profit Margin: 6617 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 6617 is unprofitable, and losses have increased over the past 5 years at a rate of 9.5% per year.
Accelerating Growth: Unable to compare 6617's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6617 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.4%).
Return on Equity
High ROE: 6617 has a negative Return on Equity (-16.75%), as it is currently unprofitable.
How is Gongwin Biopharm Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: 6617's short term assets (NT$589.6M) exceed its short term liabilities (NT$47.1M).
Long Term Liabilities: 6617's short term assets (NT$589.6M) exceed its long term liabilities (NT$33.2M).
Debt to Equity History and Analysis
Debt Level: 6617's debt to equity ratio (3.2%) is considered satisfactory.
Reducing Debt: 6617's debt to equity ratio has increased from 1.7% to 3.2% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6617 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 6617 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 14% each year
What is Gongwin Biopharm Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 6617's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 6617's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 6617's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 6617's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 6617's dividend in 3 years as they are not forecast to pay a notable one for the TW market.
How experienced are the management team and are they aligned to shareholders interests?
Yuan Lin Mao
Yuan Lin Mao serves as General Manager at Gongwin Biopharm Holdings Company. Yuan Lin Ma serves as General Manager at Gongwin Biopharm Co.Ltd. Many year of financial operations experience in Taiwan, China,...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6%.
Gongwin Biopharm Holdings Co., Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: Gongwin Biopharm Holdings Co., Ltd.
- Ticker: 6617
- Exchange: GTSM
- Founded: 2014
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: NT$25.459b
- Shares outstanding: 109.26m
- Website: https://www.gongwinbiopharm.com
- Gongwin Biopharm Holdings Co., Ltd.
- No. 80, Jianguo North Road
- 3rd Floor
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|6617||GTSM (Taipei Exchange)||Yes||Ordinary Shares||TW||TWD||Feb 2017|
Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/23 08:40|
|End of Day Share Price||2021/01/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.